The First New Oral Gonorrhoea Pills in Decades (Nuzolvence & Blujepa) and 30-Minute At-Home PCR STI Tests: Dosing, Throat-Infection Limits, and Rules by Country
Two first-in-class oral gonorrhoea antibiotics—Nuzolvence (zoliflodacin) and Blujepa (gepotidacin)—and the 30-minute Visby Medical at-home PCR test offer new options amid record STI surges. Here is how they compare to ceftriaxone injections and why throat infections differ.
Quick Answer (Checked 28 October 2026)
Three clinical updates are reshaping how bacterial STIs are tested and treated in late 2026:
- First New Oral Gonorrhoea Antibiotics in Decades: The U.S. FDA approved two first-in-class oral treatments for uncomplicated urogenital gonorrhoea: Nuzolvence (zoliflodacin)—a single
3 goral dose of granules dissolved in water (`91%` cure rate in a 930-patient Phase 3 trial)—and Blujepa (gepotidacin)—two3,000 mgoral tablet doses taken 10–12 hours apart with food (`93%` cure rate in the 628-patient EAGLE-1 trial). - The Throat-Infection Catch: Both new oral medicines are approved only for uncomplicated urogenital gonorrhoea (urethra/cervix). Intramuscular ceftriaxone injection (`500 mg` to `1 g` IM) remains the global first-line standard—and is critical whenever throat (pharyngeal) gonorrhoea is possible, because oral antibiotics clear throat infections far less reliably.
- 30-Minute Prescription-Free At-Home PCR STI Testing: Alongside new oral therapies and record gonorrhoea and syphilis notifications across Europe (ECDC) and Australia (Kirby Institute), the FDA authorized the Visby Medical Women’s Sexual Health Test—a palm-sized, non-prescription true PCR device that screens a self-collected vaginal swab at home for chlamydia, gonorrhoea, and trichomoniasis in ~30 minutes with `>97%` accuracy.
For more than a decade, getting treated for gonorrhoea in a clinic meant one thing: an intramuscular injection of ceftriaxone into the buttock or thigh. One by one, *Neisseria gonorrhoeae* evolved resistance to older oral pills—first sulfonamides and penicillins, then tetracyclines, then fluoroquinolones like ciprofloxacin, and increasingly macrolides like azithromycin.
At the same time, public-health agencies in 2026 reported historic bacterial STI surges: European Centre for Disease Prevention and Control (ECDC) surveillance showed European gonorrhoea cases up 303% over a decade (`106,331` annual notifications) and syphilis more than doubled (`45,577` cases), while Australia’s UNSW Kirby Institute reported 10-year rises of 57% in gonorrhoea (`42,393` notifications) and 56% in infectious syphilis. Against that backdrop, two breakthroughs highlighted in October 2026 clinical reviews—the first new oral gonorrhoea drug classes in 30 years and the first 30-minute over-the-counter home PCR test—change what patients can ask for, provided you know their anatomical limits.
1. Nuzolvence (zoliflodacin) vs Blujepa (gepotidacin) vs Ceftriaxone injection: how the regimens compare
Both Nuzolvence (zoliflodacin) and Blujepa (gepotidacin) attack bacterial DNA replication through brand-new chemical mechanisms, allowing them to kill *Neisseria gonorrhoeae* strains that resist older antibiotics:
- Nuzolvence (zoliflodacin): A first-in-class spiropyrimidinetrione developed through a global public–private partnership between Innoviva/Entasis Therapeutics and the non-profit Global Antibiotic Research & Development Partnership (GARDP). It blocks bacterial DNA gyrase at the GyrB subunit—a different binding pocket from ciprofloxacin—and is taken as a single 3-gram packet of granules stirred into water.
- Blujepa (gepotidacin): A first-in-class triazaacenaphthylene antibiotic developed by GSK that inhibits two bacterial type II topoisomerase enzymes simultaneously (GyrA and ParC). Originally cleared for uncomplicated urinary tract infections (`1,500 mg` twice daily for 5 days), its gonorrhoea regimen uses a higher two-dose burst: 3,000 mg (four 750 mg tablets) taken orally with food, followed by a second 3,000 mg dose 10 to 12 hours later (`6,000 mg` total).
| Feature / Clinical Rule | Standard Ceftriaxone Injection (Global First-Line Standard) |
Nuzolvence (Zoliflodacin) (Oral Granules) |
Blujepa (Gepotidacin) (Oral Tablets) |
|---|---|---|---|
| Antibiotic Class | Third-generation cephalosporin (β-lactam) | First-in-class spiropyrimidinetrione (DNA gyrase GyrB inhibitor) | First-in-class triazaacenaphthylene (dual GyrA + ParC topoisomerase inhibitor) |
| Exact Dosing Regimen | Single intramuscular (IM) injection: • US CDC: 500 mg IM (`1 g IM` if weight ≥150 kg)• UK BASHH / EU IUSTI: 1 g IM |
Single 3-gram oral dose of granules dissolved in water (follow mixing instructions regarding food/fasting status). | Two 3,000 mg oral doses (four 750 mg tablets per dose) taken 10 to 12 hours apart after a meal (`6,000 mg` total). |
| Age & Weight Eligibility | All ages (weight-adjusted in children; safe in pregnancy) | Age ≥12 years weighing ≥35 kg (77 lb); non-pregnant patients. | Age ≥12 years weighing ≥45 kg (99 lb) with limited or no alternative options. |
| Phase 3 Urogenital Cure Rate | 96%–98%+ microbiological clearance at 4–10 days | 90.9% (`91%`) in 930-patient Phase 3 trial (The Lancet; non-inferior to comparator) | 92.6% (`93%`) in 628-patient EAGLE-1 Phase 3 trial (The Lancet vs `91.2%` comparator) |
| Throat (Pharyngeal) & Rectal Infections | Gold standard for pharyngeal, rectal, and urogenital sites | Approved ONLY for urogenital site. Not reliable as standalone therapy for pharyngeal gonorrhoea; test-of-cure required if throat exposed. | Approved ONLY for urogenital site. Limited pharyngeal numbers in EAGLE-1 (with 2 pharyngeal failures); requires pharyngeal test-of-cure. |
| Key Side Effects & Warnings | Injection-site soreness; rare cephalosporin allergy | Headache, dizziness, nausea, diarrhoea, transient low WBC; animal embryo-fetal & male fertility warnings (avoid in pregnancy). | GI effects (diarrhoea, nausea, abdominal cramping, soft stools due to acetylcholinesterase inhibition); QTc / CYP3A4 precautions. |
2. The critical clinical catch: why throat (pharyngeal) gonorrhoea still needs an injection and a Test-of-Cure
As public-health clinical advisories (such as CDPH’s May 2026 guidance) emphasize, the single biggest mistake patients and urgent-care clinics make with gonorrhoea is treating a urine test alone while missing the throat:
- 90%+ of throat and rectal gonorrhoea has zero symptoms: Performing oral sex on a partner with urethral or cervical gonorrhoea frequently transmits *Neisseria gonorrhoeae* to the tonsils and pharynx without causing a sore throat. As we detail in What a “Standard” STI Panel Includes, What It Misses, and How to Ask, a urine sample only checks the urethra—it never detects a throat or rectal infection unless you swab those sites.
- Why oral pills struggle in the throat: Tonsillar crypts have lower antibiotic tissue penetration than the urethra or cervix, where urine concentrates drug metabolites. Even with older oral alternatives like cefixime 800 mg, pharyngeal cure rates lag far behind intramuscular ceftriaxone.
- The 7-to-14-Day Test-of-Cure + 7-Day Abstinence Rule: Whether you are treated with an intramuscular ceftriaxone injection or an oral regimen (*Nuzolvence* or *Blujepa*), you must abstain from all sexual contact for 7 full days after completing treatment (and until all partners have completed treatment and symptoms have resolved). If you have pharyngeal gonorrhoea—or received any oral alternative regimen—guidelines require a Test-of-Cure (TOC) swab 7 to 14 days after treatment, followed by routine retesting at 3 months because reinfection from untreated network partners is common.
- Remember chlamydia co-treatment: Neither ceftriaxone nor *Nuzolvence* nor *Blujepa* reliably treats co-existing *Chlamydia trachomatis*. Unless chlamydia has been ruled out by a modern nucleic acid amplification test (NAAT/PCR), standard guidelines add doxycycline 100 mg orally twice daily for 7 days.
3. 30-minute at-home PCR (*Visby Medical*) vs rapid fingerstick vs clinic/postal lab kits
For years, “at-home STI test” meant pricking your finger or swabbing at home, dropping a box into a postbox, and waiting 3 to 7 business days for a central laboratory to run PCR. In 2025–2026, FDA De Novo authorizations created a new category: true point-of-care molecular PCR and rapid immunoassays you run on your own bathroom counter in 15 to 30 minutes.
| Home Testing Option | What It Tests & Sample Type | Time to Result & Accuracy | Window Period & Country Availability (2026) |
|---|---|---|---|
| Visby Medical Women’s Sexual Health Test (Single-use powered home PCR device) |
Chlamydia, Gonorrhoea & Trichomoniasis Sample: Self-collected vaginal swab (symptomatic or asymptomatic women) |
~30 minutes at home via Visby App • Chlamydia: 98.8% sens / 97.2% spec• Gonorrhoea: 99.1% sens / 100% spec• Trichomoniasis: 98.5% sens / 97.8% spec |
Window period: 7 to 14 days post-exposure. Availability: FDA De Novo OTC cleared in the US (no prescription needed). Does not test urine, throat, or rectal swabs. |
| First To Know Syphilis Test (NOWDiagnostics lateral-flow immunoassay) |
Treponemal syphilis antibodies Sample: Single drop of fingerstick blood |
~15 minutes at home Requires confirmatory lab testing (RPR + treponemal) if positive |
Window period: 3 to 12 weeks post-exposure. Crucial rule: Anyone who EVER had syphilis in the past will test positive for life on treponemal rapid tests—use a clinic RPR titer instead. |
| Multi-Site Postal Lab NAAT Kits (UK NHS SH:24 / Sexual Health London; US/CA/AU telehealth mail-in kits) |
Chlamydia, Gonorrhoea (3-site: urine/vaginal + throat + rectal), HIV & Syphilis | 2 to 5 days after mailing to accredited laboratory (`>98%` NAAT sensitivity across anatomical sites) | UK: Free via NHS postal sexual health services. US/CA/AU/EU: Covered by public clinics, telehealth platforms, or private pharmacies. |
4. Matching your test and treatment to the right timeline clock
- Within 72 hours of condomless exposure: Testing 24 hours after sex will miss an infection acquired the night before because bacteria and antibodies have not yet reached detectable levels (see STI Test Window Periods: When to Test and Retest and Confidential Postal STI Testing Routes by Country). If you are within 72 hours of condomless sex in a high-incidence network, check our DoxyPEP 72-Hour STI Prevention Guide (noting that while DoxyPEP cuts syphilis and chlamydia by 70%–88%, high tetracycline resistance means it cannot be relied on to prevent gonorrhoea in the UK/EU/Australia).
- At Day 7–14: Run your urogenital/vaginal PCR (such as *Visby Medical* at home or a clinic/postal 3-site NAAT covering throat and rectum if you had oral or anal exposure).
- If your home test turns positive: Do not take leftover antibiotics from a cabinet. Share your digital PCR readout with a licensed clinician or sexual health clinic (Talk to a Real Clinician) so you receive either standard intramuscular ceftriaxone or—if you have needle phobia, a cephalosporin allergy, or cannot reach an injection clinic for an uncomplicated urogenital infection—a weight-verified prescription for Nuzolvence (zoliflodacin) or Blujepa (gepotidacin).
Sources and evidence notes
- U.S. Food and Drug Administration (FDA). FDA Approves Two Oral Therapies to Treat Gonorrhea (Nuzolvence [zoliflodacin] and Blujepa [gepotidacin]). FDA Press Announcement.
- California Department of Public Health (CDPH). Clinical Recommendations for Recently Approved Oral Treatment of Uncomplicated Urogenital Gonorrhea. May 2026. CDPH Clinical Guidance PDF.
- HCPLive. FDA Approves Zoliflodacin (Nuzolvence) Granules for Uncomplicated Urogenital Gonorrhea. September 2026. HCPLive.
- Contagion Live. Reviewing Recently Approved Antibiotics for Uncomplicated Urogenital Gonorrhea (EAGLE-1 Gepotidacin & Zoliflodacin Phase 3 Trials). August 2026. Contagion Live.
- Contemporary OB/GYN. Sexual Health Clinical & Regulatory Updates: FDA Approval of Visby Medical At-Home STI Test, Zoliflodacin, and Gepotidacin. 20 October 2026. Contemporary OB/GYN.
- European Centre for Disease Prevention and Control (ECDC) / BBC News. Gonorrhoea and syphilis hit record levels in Europe. May 2026. BBC Health / ECDC.
- UNSW Kirby Institute / The Guardian. Gonorrhoea and syphilis rise by more than 50% in Australia. September 2026. The Guardian / Kirby Institute.
Evidence checked: 28 October 2026. Educational clinical and regulatory synthesis only; does not replace evaluation and prescription by a qualified clinician.
